File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Alendronate therapy in men with primary hyperparathyroidism.

TitleAlendronate therapy in men with primary hyperparathyroidism.
Authors
Issue Date2009
Citation
Endocrine Practice : Official Journal Of The American College Of Endocrinology And The American Association Of Clinical Endocrinologists, 2009, v. 15 n. 7, p. 705-713 How to Cite?
AbstractOBJECTIVE: To determine the skeletal effects of alendronate therapy in men with primary hyperparathyroidism (PHPT) in comparison with those in postmenopausal women. METHODS: There essentially are no published data on the effects of bisphosphonate therapy in men with PHPT. We previously conducted a double-blind, randomized, single- crossover trial of alendronate, 10 mg daily, in PHPT and reported that alendronate significantly increases bone mineral density (BMD) at 12 months relative to baseline values. That study sample included both women (n = 28) and men (n = 9) and both premenopausal (n = 4) and postmenopausal (n = 24) women. Study subjects were randomly assigned to receive either alendronate or placebo during the first year, and all subjects received alendronate during the second year. Among the men, 3 received alendronate and 6 received placebo during the first year. The current analysis focuses on the skeletal effects of alendronate therapy in the 9 men during their first year of treatment versus the 6 men during their first year while receiving placebo as well as the 24 postmenopausal women during their first year of alendronate therapy. Paired t tests comparing baseline and 12-month data were performed for the 9 treated men and the 6 control subjects; unpaired t tests were used to compare the 9 treated men and the 24 treated women. RESULTS: Alendronate therapy for 1 year (n = 9) resulted in a 4.8% increase in BMD at the lumbar spine (P = .1) in comparison with the men who received 1 year of placebo (n = 6). Relative to baseline, men receiving alendronate showed a significant 4.4% gain in BMD at the lumbar spine (P = .009) and a 2.95% gain in total hip BMD (P =.027). A 47% decline in serum levels of bone-specific alkaline phosphatase activity was also noted with alendronate therapy (P = .003). Changes in BMD in the male population were similar to previously reported effects of alendronate therapy in postmenopausal women with PHPT. CONCLUSION: Alendronate therapy in men with PHPT is associated with improvements in BMD and reductions in bone turnover. These data, similar to the findings in postmenopausal women with PHPT, suggest that aminobisphosphonates may be of value in providing skeletal protection for men with PHPT. Further study is needed to confirm skeletal protection and fracture efficacy in this population.
Persistent Identifierhttp://hdl.handle.net/10722/163295
ISSN
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKhan, AAen_US
dc.contributor.authorBilezikian, JPen_US
dc.contributor.authorKung, Aen_US
dc.contributor.authorDubois, SJen_US
dc.contributor.authorStandish, TIen_US
dc.contributor.authorSyed, ZAen_US
dc.date.accessioned2012-09-05T05:29:45Z-
dc.date.available2012-09-05T05:29:45Z-
dc.date.issued2009en_US
dc.identifier.citationEndocrine Practice : Official Journal Of The American College Of Endocrinology And The American Association Of Clinical Endocrinologists, 2009, v. 15 n. 7, p. 705-713en_US
dc.identifier.issn1934-2403en_US
dc.identifier.urihttp://hdl.handle.net/10722/163295-
dc.description.abstractOBJECTIVE: To determine the skeletal effects of alendronate therapy in men with primary hyperparathyroidism (PHPT) in comparison with those in postmenopausal women. METHODS: There essentially are no published data on the effects of bisphosphonate therapy in men with PHPT. We previously conducted a double-blind, randomized, single- crossover trial of alendronate, 10 mg daily, in PHPT and reported that alendronate significantly increases bone mineral density (BMD) at 12 months relative to baseline values. That study sample included both women (n = 28) and men (n = 9) and both premenopausal (n = 4) and postmenopausal (n = 24) women. Study subjects were randomly assigned to receive either alendronate or placebo during the first year, and all subjects received alendronate during the second year. Among the men, 3 received alendronate and 6 received placebo during the first year. The current analysis focuses on the skeletal effects of alendronate therapy in the 9 men during their first year of treatment versus the 6 men during their first year while receiving placebo as well as the 24 postmenopausal women during their first year of alendronate therapy. Paired t tests comparing baseline and 12-month data were performed for the 9 treated men and the 6 control subjects; unpaired t tests were used to compare the 9 treated men and the 24 treated women. RESULTS: Alendronate therapy for 1 year (n = 9) resulted in a 4.8% increase in BMD at the lumbar spine (P = .1) in comparison with the men who received 1 year of placebo (n = 6). Relative to baseline, men receiving alendronate showed a significant 4.4% gain in BMD at the lumbar spine (P = .009) and a 2.95% gain in total hip BMD (P =.027). A 47% decline in serum levels of bone-specific alkaline phosphatase activity was also noted with alendronate therapy (P = .003). Changes in BMD in the male population were similar to previously reported effects of alendronate therapy in postmenopausal women with PHPT. CONCLUSION: Alendronate therapy in men with PHPT is associated with improvements in BMD and reductions in bone turnover. These data, similar to the findings in postmenopausal women with PHPT, suggest that aminobisphosphonates may be of value in providing skeletal protection for men with PHPT. Further study is needed to confirm skeletal protection and fracture efficacy in this population.en_US
dc.languageengen_US
dc.relation.ispartofEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistsen_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshAlendronate - Pharmacology - Therapeutic Useen_US
dc.subject.meshBone Density - Drug Effectsen_US
dc.subject.meshBone Density Conservation Agents - Pharmacology - Therapeutic Useen_US
dc.subject.meshCross-Over Studiesen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHyperparathyroidism, Primary - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshPostmenopauseen_US
dc.subject.meshPremenopauseen_US
dc.subject.meshSex Factorsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleAlendronate therapy in men with primary hyperparathyroidism.en_US
dc.typeArticleen_US
dc.identifier.emailKung, A:awckung@hku.hken_US
dc.identifier.authorityKung, A=rp00368en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.4158/EP08178.ORRen_US
dc.identifier.pmid19625240-
dc.identifier.scopuseid_2-s2.0-77449100380en_US
dc.identifier.volume15en_US
dc.identifier.issue7en_US
dc.identifier.spage705en_US
dc.identifier.epage713en_US
dc.identifier.isiWOS:000273483300007-
dc.identifier.scopusauthoridKhan, AA=7404909430en_US
dc.identifier.scopusauthoridBilezikian, JP=19641646600en_US
dc.identifier.scopusauthoridKung, A=7102322339en_US
dc.identifier.scopusauthoridDubois, SJ=7005784023en_US
dc.identifier.scopusauthoridStandish, TI=6602780002en_US
dc.identifier.scopusauthoridSyed, ZA=35263018400en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats